impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

One year in review

 

Behçet's syndrome: one year in review 2022

1, 2, 3, 4, 5, 6

 

  1. Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  2. Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  3. Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  5. Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, Istanbul, and Division of Ophthalmology, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey.
  6. Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, Istanbul, Turkey. vhamuryudan@yahoo.com

CER15870
2022 Vol.40, N°8
PI 1461, PF 1471
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 35894066 [PubMed]

Received: 23/05/2022
Accepted : 15/07/2022
In Press: 26/07/2022
Published: 14/09/2022

Abstract

This review highlights publications on different aspects of Behçet’s syndrome (BS) that appeared in 2021 and provides a critical view. These publications include works on the epidemiology of BS across different continents, newly developed instruments to assess damage in BS, studies highlighting the immunopathogenesis, genetics and epigenetic factors, histopathology of the pathergy lesion, clinical and imaging aspects of vascular involvement, and safety and efficacy of therapeutic agents including tocilizumab, apremilast and direct oral anticoagulants.

DOI: https://doi.org/10.55563/clinexprheumatol/h4dkrs

Rheumatology Article